51
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC
Biotwitter is great for healthy debates. The most recent has been on the merits of the hybrid vs.an in-person model. John Maraganore’s excellent article on the topic and the ensuing discussion articulated what’s been on the minds of most CEOs, executive teams and board members I’ve interacted with over the last few months.
The public health environment (knock on all the wood you have) might finally be at a place where we can plan for a team working model for the medium term. This requires us to answer two important questions…